BioSpace News Archive

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.

Vistagen announced that its Chief Executive Officer, Shawn Singh, will participate in the Healthcare Virtual Conference presented by Maxim Group LLC taking place June 20 – 22, 2023 virtually on the M-Vest platform.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. announced that it will be presenting data on ELYXYB™ for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society to be held on June 14-18, 2023 in Austin, Texas.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) today announced that as part of the Company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) (“SciSparc”) it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind’s and SciSparc’s combination treatment for obesity and metabolic syndrome.

TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.

Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs” or “Company”) today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other malignant tumors, has been approved by the FDA (U.S. Food and Drug Administration).

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective , Mary Sue Coleman, former Independent Director of Johnson & Johnson, has been appointed to the Company’s Board of Directors.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that the U.S. Food and Drug Administration (FDA) has approved its application for premarket approval (PMA) of its RECELL® System for the treatment of vitiligo.

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-811 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab and chemotherapy met one of its dual primary endpoints of progression-free survival for the first-line treatment of human epidermal growth factor receptor 2 -positive advanced gastric or gastroesophageal junction adenocarcinoma.